Axsome Therapeutics, a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, entered into a $570 million term loan and revolving credit facility with funds managed by Blackstone Life Sciences and...
Read Story
May 14, 2025, 08:05 AM
|
Axsome Therapeutics announced that its existing term loan facility agreement with Hercules Capital has been amended to increase the size of the facility to $300 million, and the amount immediately available upon U.S. Food and Drug Administration...
Read Story
October 19, 2021, 07:49 AM
|